RIPK2 and neoplasm: Furthermore, deletion of receptor‐interacting protein kinase 2 (RIPK2), a key regulator of the tumour microenvironment, disrupts NBR1‐mediated degradation and further augments MHC‐I surface expression, ultimately sensitizing PDAC tumours to anti–PD‐1 immunotherapy.63